The European Forum for GCP (EFGCP) has moved its annual two-day conference from the traditional slot in late January to the beginning of March.
Under the title of “Bringing together the two worlds of medicine & device research to better serve public, patients & research participants,” EFGCP Annual Conference 2016 will take place on March 1 and 2, in Brussels, Belgium.
The aim of the event is to help the two worlds of pharma and medical devices develop research, medicines and equipment for patient benefit.
“The EU Medical Device regulations are almost upon us. These will have significant consequences, similar to the Clinical Trail Regulations and there is an opportunity to learn from pharma experience,” noted EFGCP in a statement issued October 1.
The meeting will outline what regulations will mean to the devices industry and focus on the lessons learnt from experience with the clinical trial regulations. The tangible outcomes will be an EFGCP report and recommendations that will be provided to those involved in the legislative process.
For 22 years the European Forum for Good Clinical Practice has acted as a forum to bring patients, researchers, sponsors, competent authorities and ethics committees together and debate current topics. It is recognized as an important forum for multi-stakeholder debate.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.